How Will The Existence Of Medical And Pharmacy Benefits In The Market Basket For Ulcerative Colitis Affect Formulary Strategy?

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).